GO
Loading...

Schering-Plough Beats Earnings Forecasts By Wide Margin

Schering-Plough reported strong first-quarter results, surpassing consensus estimates by a wide margin due to strong sales of cholesterol drugs and allergy treatments.

Schering-Plough on Thursday morning announced first-quarter earnings growth of 55%, beating analysts' estimates on sharply higher sales of its prescription drugs, including two cholesterol fighters sold in partnership with Merck .

Profit rose 55% to $543 million, or 36 cents a share, from $350 million, or 24 cents a share, in the year-ago period.

Excluding one-time items, the Kenilworth, N.J.-based pharmaceutical company reported earnings of 42 cents a share. Analysts expected Schering-Plough to report 29 cents a share, according to Thomson Financial.

Sales in the period jumped 17% over last year to $3.0 billion before revenue from cholesterol drugs Vytorin and Zetia, which the drugmaker markets with Merck. Sales would have jumped 21% in the period including the co-marketed medicines.

Sales of allergy drugs Nasonex and Clarinex both came in above Wall Street estimates. The drugmaker also got a boost from arthritis treatment Remicade, which jumped 34% to $373 million in the first quarter. Schering-Plough sells Remicade outside of the U.S. and Japan under license from Johnson & Johnson.

"This was largely a quality revenue-driven beat," said Tim Anderson, pharma analyst with Prudential Equity Group. "The 'whisper' was that Schering-Plough could beat by a significant margin, and they did. Other drug companies have also beat thus far this quarter, and those that have yet to report will probably beat as well."

Contact U.S. News

  • CNBC NEWSLETTERS

    Get the best of CNBC in your inbox

    Please choose a subscription

    Please enter a valid email address
    To learn more about how we use your information,
    please read our Privacy Policy.

Don't Miss

  • The Glass Ceiling

    Full-time working women still only earn about 77% of what men do in the same fields. A lawsuit in Silicon Valley is bringing renewed focus to that statistic. Vanity Fair Contributing Editor Bethany McLean on the equality fight for women's pay and promotion.

  • Man takes off work clothes on beach

    With Ruth Porat leaving Wall Street for Silicon Valley, Turney Duff takes a look at other ex-Wall Street friends and where they are now.

  • A group of scientists believe they've cracked the reason behind a big mystery: Why are beards so popular?

U.S. Video